Up-regulation of striatal adenosine A2A receptors in schizophrenia

NeuroReport

Volumn 14, Issue 3, 2003, Pages 313-316

  Deckert, Jürgen ^a,b   Brenner, Markus ^a   Durany, Nuria ^a,c   Zöchling, Robert ^d   Paulus, Werner ^b   Ransmayr, Gerhard ^e   Tatschner, Thomas ^a   Danielczyk, Walter ^f   Jellinger, Kurt ^g   Riederer, Peter ^a  

^a UNIVERSITY OF WÜRZBURG   (Germany)

^b UNIVERSITY OF MÜNSTER   (Germany)

^c UNIVERSITAT INTERNACIONAL DE CATALUNYA   (Spain)

^d Stt Hosp Neurol/Psychiat Mauer   (Austria)

^e UNIVERSITY OF VIENNA   (Austria)

^f LUDWIG BOLTZMANN INSTITUTE FOR LUNG VASCULAR RESEARCH   (Austria)

^g GENERAL HOSPITAL LINZ   (Austria)

Author keywords

Adenosine A2A receptor; Antipsychotic drugs; Caffeine; Human striatum; Schizophrenia

Indexed keywords

2 [4 (2 CARBOXYETHYL)PHENETHYLAMINO]ADENOSINE 5' (N ETHYLCARBOXAMIDE); ADENOSINE A2 RECEPTOR; CAFFEINE; CHLORPROMAZINE;

ADULT; AGED; ARTICLE; AUTOPSY; CLINICAL ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; FEMALE; HUMAN; HUMAN TISSUE; MALE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RECEPTOR AFFINITY; RECEPTOR DENSITY; SCHIZOPHRENIA;

EID: 0037416297     PISSN: 09594965     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001756-200303030-00003     Document Type: Article

References (25)

1. Lucas PB, Pickar D, Kelsoe J et al. Biol Psychiatry 28, 35-40 (1990).
2. Daly JW, Bruns RF and Snyder SH. Life Sci 28, 2083-2097 (1981).
3. Schiffmann SN, Jacobs O and Vanderhaegen JJ. J Neurochem 57, 1062-1067 (1991).
4. Fink JS, Weaver DR, Rivkees SA et al. Mol Brain Res 14, 186-195 (1992).
5. Green RD, Proudfit HK and Yeung SMH. Science 218, 58-61 (1982).
6. Ferre S, Snaprud P and Fuxe K. Eur J Pharmacol Mol Pharmacol Sect 244, 311-315 (1993).
7. Heffner TG, Wiley JN, Williams AE et al. Psychopharmacology 98, 31-37 (1989).
8. Ferre S, Rubio A and Fuxe K. Neurosi Lett 130, 162-164 (1991).
9. Deckert J and Gleiter CH. Trends Pharmacol Sci 10, 99-100 (1989).
10. Ferre S, O'Connor WT, Snaprud P et al. Neuroscience 63, 765-773 (1994).
11. Deckert J, Nöthen MM, Rietschel M et al. J Neural Transm 103, 1447-1455 (1996).
12. Deckert J, Nöthen MM, Byrant SP et al. Hum Genet 99, 326-328 (1997).
13. Jarvis MF, Schulz R, Hutchison AJ et al. J Pharmacol Exp Ther 251, 888-893 (1989).
14. Baldessarini RJ, Katz B and Cotton P. Am J Psychiatry 141, 748-752 (1984).
15. Wyatt RJ. Psychopharmacol Bull 12, 5-50 (1976).
16. McPherson GA. J Pharmacol Methods 14, 213-228 (1985).
17. Rihs M, Muller C and Baumann P. Eur Arch Psychiatry Clin Neurosci 246, 83-92 (1996).
18. Ferre S, Schwarcz R, Li XM et al. Psychopharmacology 116, 279-284 (1994).
19. Parsons B, Togasaki DM, Kassir S et al. J Neurochem 65, 2057-2064 (1995).
20. Ferre S, von Euler G, Johannson B et al. Proc Natl Acad Sci USA 88, 7238-7241 (1991).
21. Diaz-Cabiale Z, Hurd Y, Guidolin D et al. Neuroreport 12, 1831-1834 (2001).
22. Hillion J, Canals M, Torvinen M et al. J Biol Chem 277, 18091-18097 (2002).
23. Creese I, Burt DR and Snyder SH. Science 192, 481-483 (1976).
24. Kornhuber J, Riederer P, Reynolds GP et al. J Neural Transm 75, 1-10 (1989).
25. Kafka SH and Corbett R. Eur J Pharmacol 295, 147-154 (1996).